Stig Lenhoff (Former)
31 – 40 of 53
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
(
- Contribution to journal › Article
- 2012
-
Mark
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT
(
- Contribution to journal › Article
-
Mark
The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Factors associated with changes in quality of life in patients undergoing allogeneic haematopoietic stem cell transplantation.
2012) In European Journal of Cancer Care(
- Contribution to journal › Article
- 2011
-
Mark
Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party
(
- Contribution to journal › Article
- 2010
-
Mark
Multiparametric Flow Cytometry Profiling of Neoplastic Plasma Cells in Multiple Myeloma
(
- Contribution to journal › Article
-
Mark
Effective CD3 T-cell depletion using the CliniMacs (R) System to produce peripheral blood progenitor cell products for haploidentical transplantation in 23 children and adults: the updated Lund experience
2010) 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting In Bone Marrow Transplantation 45(Suppl.2). p.325-325(
- Contribution to journal › Published meeting abstract
-
Mark
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT
(
- Contribution to journal › Article
-
Mark
Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200 Patients in Trials of the Nordic Myeloma Study Group
(
- Contribution to journal › Article
- 2009
-
Mark
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
(
- Contribution to journal › Published meeting abstract